Oztuzcu, SerdarUlasli, MustafaPehlivan, YavuzCevik, Muhammer OzgurCengiz, BeyhanGogebakan, BulentIgci, Yusuf Ziya2024-09-182024-09-1820130196-97811873-5169https://doi.org/10.1016/j.peptides.2012.12.013https://hdl.handle.net/20.500.12483/12727Behcet's disease (BD) is multisytemic vasculitis or chronic inflammation that may lead to various autoimmune and autoinflammatory syndromes. Exact etiopathogenesis of BD has not been clarified yet. Urotensin II (UTS-II) is predominantly a vasoactive peptide and Thr21Met polymorphism in UTS-II gene was proved to increasing in some autoimmune diseases. Considering these, our objective was to evaluate whether two UTS-II gene polymorphisms (Thr21Met and Ser89Asn) were responsible in genetic susceptibility to BD in a Turkish population. A total of 198 patients with BD and 275 healthy controls were enrolled. We analyzed the genotype and allele frequencies of two UTS-II gene polymorphisms, Thr21Met and Ser89Asn, in BD patients and in controls. We found that Thr21Met but not Ser89Asn polymorphisms of the UTS-II gene were markedly associated with the risk of developing BD (p<0.0001), The Met21Met genotype was less common among BD patients (6.1% in patients vs. 17.1% in controls; p<0.0001). There was also an increase in the 21Thr allele (54.8% in BD patients vs. 43.8% in controls) and a decrease in 21Met allele frequencies (45.2% in controls vs. 56.2% in patients) in the BD groups (p<0.0044). To the best of our knowledge, for the first time in the literature, our study claims that there is an association between Thr21Met, and not between Ser89Asn polymorphisms in the UTS-II gene and BD. These results put a new player to the field of undiscovered pathogenesis of BD and hopefully provide new insights to the treatment options. Crown Copyright (C) 2012 Published by Elsevier Inc. All rights reserved.eninfo:eu-repo/semantics/closedAccessUrotensin-II genePolymorphismsBehcet's diseaseArticle429710010.1016/j.peptides.2012.12.013233334812-s2.0-84874547133Q2WOS:000320492800014Q2